Modified Immune Cell Culture via Target Protein Reduction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Immune cells used in immunotherapy suffer from weak cell function and poor proliferation and survival capabilities after reinfusion, necessitating a robust and reliable culture method to enhance their efficacy.
Innovation Solution
A method of culturing cells by reducing the expression and/or activity of peptidase C64, ZC3H12, STAT-induced STAT inhibitor (SSI), and CBL family members to enhance target cell killing ability, cytokine release, and increase the proportion of activated, central memory, and naive cells while decreasing regulatory and exhausted cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional immune cell culture methods are used, then the culture process is simple, but the cell function and proliferation capability are weak
Solution Approach 1:
The patent modifies the cellular environment by reducing the expression or activity of specific protein families (peptidase C64, ZC3H12, SSI, and CBL) through genetic engineering approaches. This parameter change in protein expression levels leads to enhanced cell function, improved proliferation capability, and increased survival rates of the cultured immune cells, directly resolving the contradiction between simple culture methods and weak cell function.
2Duration of action of moving object
If immune cells are reinfused into the body, then they can perform immunotherapy, but their survival capability and proliferation are poor
Solution Approach 1:
The patent applies preliminary genetic modification to immune cells before reinfusion, specifically reducing the expression or activity of peptidase C64, ZC3H12, SSI, and CBL family members. This preliminary action enhances the cells' survival capability and proliferation potential in advance, ensuring they can effectively perform immunotherapy functions after reinfusion into the patient's body, thereby resolving the contradiction between survival capability and therapeutic effectiveness.
Data Source
Figure 1A
Figure 1B
Figure 1C
AI summary
The present invention relates to the field of biomedicine, and provides a modified cell and its uses. Specifically, the present invention relates to a method of culturing cells, comprising reducing the expression and/or activity of target genes. The present invention also relates to methods of preventing and/or treating a tumor using the cultured cells.